[Skip to Navigation]
Views 473
Citations 0
Comment & Response
March 2, 2021

Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention

Author Affiliations
  • 1Department of Internal Medicine, Chosun University College of Medicine, Gwangju, South Korea
  • 2Department of Cardiology and Internal Medicine, Nicolaus Copernicus University Collegium Medicum, Bydgoszcz, Poland
  • 3Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, South Korea
JAMA. 2021;325(9):890. doi:10.1001/jama.2020.26020

To the Editor A recent retrospective cohort analysis by Dr You and colleagues1 demonstrated that compared with clopidogrel, ticagrelor was not associated with better outcomes in patients from the US and South Korea with acute coronary syndrome (ACS) undergoing percutaneous intervention (PCI). However, there are several important discrepancies between this cohort analysis and the randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.2

×